

Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ϵ -caprolactone) nanoparticles

Qin Liu^{1*}
 Ru-Tian Li^{1*}
 Han-Qing Qian²
 Mi Yang¹
 Zhen-Shu Zhu²
 Wei Wu²
 Xiao-Ping Qian¹
 Li-Xia Yu¹
 Xi-Qun Jiang²
 Bao-Rui Liu¹

¹The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing 210008, China;

²Laboratory of Mesoscopic Chemistry and Department of Polymer Science and Engineering College of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, China

*These authors contributed equally to this work

Abstract: Nanoscale drug carriers have been extensively developed to improve drug therapeutic efficiency. However, delivery of chemotherapeutic agents to tumor tissues and cells has not been favorably managed. In this study, we developed a novel “intelligent” nanoparticle, consisting of a gelatinase-cleavage peptide with poly(ethylene glycol) (PEG) and poly(ϵ -caprolactone) (PCL)-based structure for tumor-targeted docetaxel delivery (DOC-TNPs). The docetaxel-loaded PEG-PCL nanoparticles (DOC-NPs) that did not display gelatinase-stimuli behaviors were used as a control. We found clear evidence that the DOC-TNPs were transformed by gelatinases, allowing drug release and enhancing the cellular uptake of DOC ($P < 0.01$). In vivo biodistribution study demonstrated that targeted DOC-TNPs could accumulate and remain in the tumor regions, whereas non-targeted DOC-NPs rapidly eliminated from the tumor tissues. DOC-TNPs exhibited higher tumor growth suppression than commercialized Taxotere® (docetaxel; Jiangsu Hengrui Medicine Company, Jiangsu, China) and DOC-NPs on hepatic H22 tumor model via intravenous administration ($P < 0.01$). Both in vitro and in vivo experiments suggest that the gelatinase-mediated nanoscale delivery system is promising for improvement of antitumor efficacy in various overexpressed gelatinase cancers.

Keywords: drug delivery, stimuli-responsive, gelatinase, antitumor, docetaxel

Introduction

Active targeting delivery systems have become a large area of focus in cancer therapeutics. Targeting ligands, such as aptamer,¹ RGD peptide,² antibody,³ folate,⁴ are peripherally conjugated to nanocarriers for binding to particular receptors overexpressed by tumor cells or vasculatures. However, much ligand-targeted therapeutics is only effective in certain types of cancer cases. For example, the anti-HER2 antibody delivery system only increased the therapeutic index in HER2 positive tumor.⁵ Another new targeting strategy in development is employing stimuli-sensitive nanocarriers, such as thermo-sensitive micelles,⁶ magnetic nanoparticles,⁷ and photo-responsive polymers.⁸ The structures of these nanocarriers could be transformed by external or internal triggering elements, facilitating drug release from nanoparticles or interacting with the tumor cells targetedly.⁹ Although these reported nano-drugs are sensitive enough in laboratory research, limitations for clinical applications still exist. For instance, the thermo-responsive or magnetic nanocarriers need external heating or magnets to guide nanoparticles to the tumors, so the tumor locations should be clear and definite before treatment. As a result, treatment of disseminated tumors, which are an

Correspondence: Bao-Rui Liu
 The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing 210008, China
 Tel/fax +86 25 83105082
 Email baoruiliu@nju.edu.cn

obstacle of clinical therapeutics, is a great challenge for these stimuli-responsive nanocarriers.¹⁰ Therefore, exploration of more universal and targeted delivery systems is necessary for cancer therapy.

Proteases, which can recognize and hydrolyze peptide substrates, are one of the most promising triggers for stimuli-responsive drug delivery.¹¹ Considerable efforts have been made to develop protease-targeted drugs and have demonstrated promising results.¹² For example, in vitro experiments, the esterase and phospholipase A2 activated strategies have been developed to improve intercellular uptake efficacy.^{13,14} However, the environment in vivo is much more complex than that during in vitro experiments. So, it is not surprising that although some protease-stimuli strategies work effectively in vitro, the in vivo results are disappointing. In general, pervasiveness and selectivity of targeted proteases are two primary factors affecting the results of in vivo experiments.

Matrix metalloproteases (MMPs) have received great attention in cancer research due to their important role in cancer progression.¹⁵ Notably, MMPs are a large family of enzymes with different groups of MMPs playing different roles in cancer progression. Some MMPs, such as MMP12, might help defy cancers.¹⁶ Presently, many functions of MMPs are still unknown. Loss of selectivity for specific MMPs might induce side effects. Among various tumor-associated MMPs, gelatinases (MMP2/9, Collagenases IV) are known to be abundantly present in most tumors and their basic function is to degrade the extracellular matrix (ECM). Many studies have verified that gelatinases are 'bad' MMPs, playing an important role in numerous malignant tumor behaviors, such as angiogenesis, apoptosis, aggressiveness, metastasis, and poor survival.^{17,18} Therefore, gelatinases may be suitable candidates for stimuli-responsive targeted strategies, although MMP-stimuli strategies have been applied to prodrugs,¹⁹ and liposomes.^{20,21} Nanoparticles, which have their own advantages on drug delivery, using such strategies are rare. Some gelatinase-mediated drug delivery strategies do not pay attention to the different roles of MMP subtypes, which are directly related to the therapeutic effects. Therefore, we developed the gelatinase-stimuli nanoparticle for the improvement of anticancer efficacy.

We focus on the enzyme-stimuli strategy also because PEGylated nanoparticles have some shortcomings. The PEGylated nanoparticles are primarily unable to interact with tumor cells thoroughly, leading to decreased efficacy and damage to normal cells. The gelatinase-stimuli nanoparticles can strike a balance between PEGylation and

dePEGylation (Figure 1). The PEG outer shell provides nanoparticles with stealth and increases their blood circulating time. Once the nanoparticles accumulate in the tumors, the peptides are degraded by gelatinases. The PEG blocks are cleaved, and the remaining PCL blocks aggregate, resulting in PEG-uncoated nanoparticles being retained in the tumor region, efficiently reaching more tumor cells, and presenting high antitumor activity. Additionally, the carriers can easily deform without entering cells, because active gelatinases are secreted exogenously.

In the present study, the poly(ϵ -caprolactone) (PCL) polymer was chosen because of its excellent biocompatibility and biodegradability properties. To emphasize the superiority of this novel nanocarrier, we used the well-recognized, effective carriers, PEG-PCL nanoparticles as a positive control. We confirmed the specific gelatinase-responsive profile from physicochemical characterization, in vitro cellular uptake, and in vivo real-time near-infrared fluorescent (NIRF) imaging. Further, we assessed the anticancer superiority of DOC-TNPs by tumor volume observation, historical study, positron emission tomography, and computed tomography (PET/CT) real-time scanning on murine hepatic H22 tumor-bearing mice as a model for comparison to Taxotere[®] and common DOC-NPs through intravenous (IV) administration.

Materials and methods

Materials

Methoxy-polyethyleneglycol-NHS (mPEG-NHS) was purchased from Beijing Jiankai Technology Co, (Beijing, China). The gelatinase-cleavable peptide (PVGLIG) was obtained from Shanghai HD Biosciences Co (Shanghai, China). Docetaxel (DOC) and Taxotere[®] (Taxotere[®] is the commercial name of DOC) were provided by Jiangsu Hengrui Medicine Company (Jiangsu, China). Coumarin-6 and




Figure 1 The gelatinase-stimuli strategy enhanced nanoparticles interactions with cancer cells in the tumor tissues. After release from tumor capillaries, the PEG-Pep conjugates were cleaved by gelatinases, which were specifically secreted in the tumor microenvironment. The remained PCL blocks aggregated and the PEG-uncoated PCL nanoparticles interacted efficiently with cancer cells, resulting in fast drug release and effective therapeutics.

Abbreviations: PEG, poly(ethylene glycol); PCL, poly(ϵ -caprolactone); Pep, peptide.

gelatinases were purchased from Sigma-Aldrich® (St Louis, MO). ϵ -caprolactone (ϵ -CL) and dimethyl formamide (DMF) were purified by being dehydrated over CaH_2 at room temperature and distilled under reduced pressure. All other chemicals were used as received without further treatment.

Synthesis of PEG-Pep-PCL copolymers and PEG-Peptide conjugates

The mPEG-NHS (200 mg) and peptides (26 mg) were dissolved in DMF (3 mL) containing 3% Et_3N and stirred for 3 hours at room temperature to prepare PEG-Peptide conjugates. The unconjugated peptides were removed by dialysis in a 3500 Da MWCO membrane (Sigma-Aldrich) against deionized water for 24 hours.

Synthesis of PCL-NH₂ polymers

A polymerization tube containing ϵ -CL and L-leucine was evacuated and sealed off. The polymerization was carried out at 160°C for 24 hours. Then the resulting complexes were dissolved in dichloromethane (DCM) and precipitated into a large amount of cold ethyl ether to produce PCL-COOH. The DMF dissolved PCL-COOH polymers were added with 4-dimethylaminopyridine (DMAP), 1-ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride (EDC), ethylenediamine and N-hydroxysulfosuccinimide sodium salt (NHS), and stirred at 37°C for 18 hours. The mixture was precipitated in ethanol, filtered through medium speed filter paper, and dried under vacuum to prepare the PCL-NH₂.

Synthesis PEG-Pep-PCL and PEG-PCL copolymers

The mixture of PCL-NH₂ (0.002 mol), PEG-Peptide conjugates (0.002 mol), DMAP (0.003 mol), EDC (0.002 mol) and NHS (0.002 mol) in DMF was stirred for 24 hours at 32°C. The crude PEG-Peptide-PCL copolymers were purified by dialysis (MWCO 13 kDa) for 24 hours, lyophilized to powder, and stored at 4°C for further use. The PEG-PCL di-block copolymers were synthesized by a ring opening copolymerization as we previously described.²²

Preparation of DOC-loaded nanoparticles

DOC-loaded nanoparticles were prepared by a modified nano-precipitation method.²³ Briefly, 20 mg of copolymers and 10 mg of DOC were dissolved in 0.2 mL hot acetone by heating to 60°C. Subsequently, the mixture was added into 6 mL water quickly to form nanoparticles. The remaining acetone was removed by rotary vacuum evaporation. The

resultant solution was filtered to remove non-incorporated DOC and the suspension was freeze-dried for further use. The empty nanoparticles were prepared similarly in the absence of DOC.

Particle size and morphology of the particles

The particle size and polydispersity of PEG-Pep-PCL and PEG-PCL nanoparticles were measured by dynamic light scattering (DLS) (Brookhaven Instruments Corporation, NY). The values were the average of triplicate measurements for a single sample.

PEG-Pep conjugates cleavage in response to gelatinases

We then investigated the cleavage of PEG-Pep conjugates in the presence of gelatinases. PEG-Pep-PCL nanoparticles (0.25 mM) were incubated in PBS solution with or without gelatinases at 37°C for 24 h. The morphology of the nanoparticles was determined by scanning electron microscopy (SEM) (S-4800, HITACHI, Tokyo, Japan).

In vitro DOC release from the nanoparticles

Twenty-five milligram lyophilized DOC-loaded nanoparticles were redispersed in 1 mL of phosphate buffer solution (PBS, 0.01 M, pH 7.4) with or without 1 mg/mL gelatinases and put into a dialysis bag (MWCO 12 kDa). The dialysis bag was immersed into 5 mL release medium (PBS containing 0.1% v/v Tween 80® [Sigma-Aldrich]) with gentle agitation at 37°C for 96 hours.²⁴ At different time points, the release medium was withdrawn for HPLC analysis, and equivalent release medium was added.

In vitro cell uptake assays

Human colon cancer carcinoma cell line LOVO, human Lewis lung carcinoma (LLC), and murine hepatic carcinoma cell line H22 were purchased from Shanghai Institute of Cell Biology (Shanghai, China). The tumor cells were routinely cultured in RPMI 1640 medium (Sigma-Aldrich), supplemented with 10% fetal bovine serum (FBS) at 37°C. The gelatinase-stimuli property and biocompatibility of nanoparticles were confirmed by in vitro cellular uptake study. We measured the gelatinases expressions of different adherent cancerous cells by gelatin zymography (see “Supplemental data”). The colon carcinoma cells LOVO and Lewis lung cancer cells were chosen for their different gelatinases levels. 10⁵ LOVO and LLC cells were seeded in 30-mm Petri dishes and incubated with

500 μ L medium containing coumarin-6 loaded nanoparticles (6.25 μ g/mL calculated by coumarin-6) for 2 hours at 37°C. Then the media were replaced with fresh cell culture media and the fluorescent signals of cells were imaged using the laser scanning confocal microscopy (LSM710, Carl Zeiss MicroImaging GmbH, Berlin, Germany) with an excitation wavelength of 460 nm.

We also carried out the cellular uptake studies on suspended cells H22. The particles were labeled with Rhodamine B isothiocyanate, which was reacted with hydroxyl end group of PCL block in PEG-Pep-PCL copolymers. Briefly, 1 mg Rhodamine B isothiocyanate and 30 mg PEG-Pep-PCL copolymers were dissolved in 3 mL DMF, and the system was allowed to react for 10 hours. After which, the Rhodamine B-labeled PEG-Pep-PCL nanoparticles were purified by dialysis against deionized water for 48 hours. The Rhodamine B-labeled PEG-PCL nanoparticles were prepared in the same way. The H22 cell uptake studies were taken in the above mentioned way. The quantitative study was also carried out as we previously described.²⁵ Briefly, H22 cells were seeded in a 96-well black plate at a density 1×10^4 cells per well. Coumarin-6 loaded Rhodamine B-labeled PEG-Pep-PCL and PEG-PCL nanoparticles (6.25 μ g/mL calculated by coumarin-6) were added into the cultured medium and incubated for 0.5, 1, 2, and 4 hours at 37°C. At different time points, the cells were collected by centrifugation, washed three times by PBS and lysed by 200 μ L cell lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100). The fluorescence of whole cell lysate was determined by a fluorescence microplate reader (Safire, Tecan, Männedorf, Switzerland). The excitation and emission wavelength was 460 nm and 500 nm for coumarin-6, respectively. The cell uptake efficiency can be calculated by this equation:

$$\text{Uptake efficiency (\%)} = \frac{(I_{\text{sample}} - I_{\text{negative}})}{(I_{\text{positive}} - I_{\text{negative}})} \times 100\%$$

The I_{sample} , I_{positive} and I_{negative} are the fluorescence intensities of the sample, positive control and negative control, respectively. In these tests, particle suspension was added to five wells as the positive control. In contrast, the negative control refers to the nanoparticles without coumarin-6 that were added in wells with cells.

Real-time NIRF imaging

In vivo distribution of nanoparticles was studied by NIR-797 labeled nanoparticles. PEG-PCL or PEG-Pep-PCL nanoparticles were labeled with NIR-797-isothiocyanate

(Sigma-Aldrich). Briefly, 2 mg NIR-797-isothiocyanate and 200 mg PEG-Pep-PCL were dissolved in 4 mL anhydrous DMF for 18 hours with agitation. After the reaction, unconjugated NIR-797 was removed by dialysis (MWCO 3000 Da) for 2 days. The NIR-797-labeled PEG-PCL nanoparticles were prepared in the same way and lyophilized for further use. 10^7 H22 tumor cells were inoculated subcutaneously into the right axilla of ICR mice (18–22 g, 4–5 weeks, male) to establish the tumor model. The NIR-797 labeled PEG-PCL and PEG-Pep-PCL nanoparticles (equivalent to the dose DOC 10 mg/kg) were tail vein injected into H22 tumor bearing mice (the same tumor model as that in the antitumor study) on the seventh day after inoculation. The time-dependent biodistribution in mice was imaged by the Maestro™ in-vivo imaging system (CRi Inc, Woburn, MA) at 1, 2, 4, 12, 24, 48, and 72 hours after intravenous administration.

In vivo antitumor efficacy of DOC-loaded nanoparticles

All animal studies were performed in compliance with guidelines set by the Animal Care Committee at Drum Tower Hospital, Nanjing, China. ICR mice (18–22 g, 4–5 weeks, male) were inoculated with 10^7 H22 cells subcutaneously on the right axilla. Tumor dimensions were measured with vernier calipers and the volumes were calculated as follows: tumor volume (mm^3) = width² \times length/2. When the tumors reached 100 mm^3 (designated as day 1), the animals were randomized into the following treatment groups: saline (0.5 mL), empty NPs, empty TNPs, Taxotere® (10 mg/kg), DOC-NPs (10 mg/kg DOC equal), and DOC-TNPs (10 mg/kg DOC equal). For the treatment, 0.5–0.6 mL of different DOC formations and empty nanoparticles dissolved in saline were intravenously administered into the mice every 6 days, three times per day. On day 21 after the first treatment, the tumor tissues from each group were dissected and fixed in 10% neutral buffered formalin. The tumor paraffin slices with a thickness of 5 μ m were stained with hematoxylin and eosin (H&E).

In vivo PET/CT imaging

A combined PET/CT scanner (Gemini GXL, Philips, Amsterdam, The Netherlands) was used to estimate the early antitumor efficacy on Day 7 after DOC administration. After anesthesia with pentobarbital sodium (40 mg/kg), the H22 bearing mice that received Taxotere®, DOC-NPs, and DOC-TNPs were tail vein injected with approximately 100 μ Ci/0.3 mL fluorin-18-2-fluoro-2-deoxy-d-glucose (18F-FDG) as radiotracer. PET and CT images were collected

in the prone position 30 minutes after injection. The standard uptake values (SUVs) in regions of interests (ROIs) were calculated by the following equation:

$$\text{SUVs} = \frac{\text{Radioactivity concentration in ROIs } [\mu\text{Ci/cc}]}{\text{Injected dose } [\mu\text{Ci/cc}] \times \text{Animal weight [g]}}$$

Statistical analysis

The ANOVA and student's *t*-test (two tailed) were used for statistical analyses. *P*-values less than 0.05 were considered statistically significant.

Results

Characterization of PEG-Pep-PCL nanoparticles

We synthesized the PEG-Pep-PCL copolymers via ring-opening copolymerization and amidation (Figure S1 in "Supplemental data"). Comparing the ^1H NMR of PEG-Pep-PCL and PEG-PCL copolymers, the proton signal from methyl groups in the peptide (0.823–1.006 ppm) demonstrated that the specific substrates of gelatinases were successfully inserted into the intermediate of PEG and PCL blocks (Figure S2 in "Supplemental data"). The diameter of DOC-TNPs was about 85.7 nm measured by DLS and the polydispersity index was 0.131. The drug loading content was

20.3% and drug encapsulation efficiency was 80.7% with the initial feed amount of $[\text{DOC}/\text{nanoparticles}] = 1:2$ (Table S1 in "Supplemental data"). DOC-NPs were prepared as a control to investigate the carriers' property and intracellular uptake.

The SEM images verified the response of DOC-TNPs to gelatinases. As shown in Figure 2A(a), the DOC-TNP was a monolayer spherical particle with a diameter of approximately 60 nm, which was smaller than the size obtained by DLS due to the shrinking in dry state. Such size ranged nanoparticles appreciably accumulate in tumors due to the EPR effect. After co-incubation with gelatinases for 24 hours, the nanoparticles aggregated (Figure 2A(b)) and the diameters significantly increased. In addition, these reunited nanoparticles did not break up and still kept the spherical shape.

In vitro DOC release from DOC-loaded nanoparticles

To evaluate the diffusion of DOC from the inner core of nanoparticles in the presence of gelatinases, DOC-TNPs and DOC-NPs were incubated in release medium with or without gelatinases. Both nanoparticles exhibited a steady continued-release pattern with a certain amount of initial burst release and a sustained release in the following time in the absence of gelatinases (Figure S3 in "Supplemental data"). The release of DOC from DOC-TNPs exhibited faster release than that of




Figure 2 The gelatinase-stimuli characterization of PEG-Pep-PCL nanoparticles. **(A)** SEM images of PEG-Pep-PCL nanoparticles in response to gelatinases **(a)** PEG-Pep-PCL, **(b)** PEG-Pep-PCL co-incubation with gelatinases. **(B)** In vitro release of DOC from the nanoparticles in the presence of gelatinases. **(C)** The cellular uptake of coumarin-6-loaded PEG-PCL and PEG-Pep-PCL nanoparticles in two kinds of cancer cells, which express different gelatinases levels (LOVO cells expressed relatively high gelatinases compared with LLC cells).

Abbreviations: DOC, docetaxel; LLC, Lewis lung carcinoma; PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide; SEM, scanning electron microscope.

DOC-NPs in gelatinases solution (19% versus 14% at 1 hour, and 82% versus 64% at 96 hours [Figure 2B]).

In vitro cellular uptake studies

We next examined whether or not the cellular uptake efficiency of PEG-Pep-PCL nanoparticles depended on the gelatinase levels. For this purpose, we first quantified the active gelatinases via gelatin zymography to screen suitable cancer cells (Figure S4 in “Supplemental data”). Colon carcinoma cells LOVO expressing high gelatinase levels were used as a positive control for comparison with the Lewis lung cancer cells, which express relatively low gelatinases compared to LOVO cells. The fluorescence intensity of PEG-PCL in LOVO cells is weaker than LLC, while the fluorescence intensity of PEG-Pep-PCL in LOVO cells is similar to LLC (Figure 2C). The enhanced cellular uptake of coumarin-6-loaded PEG-Pep-PCL nanoparticles to PEG-PCL nanoparticles was found in both LLC and LOVO cells, and the fluorescence difference was more distinguished in LOVO cells, which relatively express more active gelatinases.

The intracellular uptake was also carried out on suspended cells H22, which highly expressed gelatinases (Figure S5 in “Supplemental data”). The nanoparticles were marked with Rhodamine B isothiocyanate to track the position of nanoparticles. Insoluble dye, coumarin-6, dispersed evenly in particles to imitate the actions of DOC. Figure 3A demonstrates that the green fluorescence from coumarin-6 and red color from Rhodamine B labeled nanoparticles were overlapped in the cytoplasm, suggesting that coumarin-6 entered cytosol together with nanoparticles. Besides the fluorescence densities of the PEG-Pep-PCL nanoparticles, treated groups were always higher than that of PEG-PCL nanoparticles, illustrating that PEG-Pep-PCL nanoparticles entered the cancer cells more efficiently. To confirm this supposition, the fluorescence microplate reader was used to quantify the cellular uptake efficiency, the ratio between the amounts of coumarin-6 loaded nanoparticles taken up by cells with the total amount. The uptake efficiency increased over the course of 4 hours, and a higher cell internalization of PEG-Pep-PCL nanoparticles was observed. Statistically, compared to PEG-PCL nanopar-




Figure 3 The in vitro H22 cellular uptake studies of nanoparticles. **(A)** Confocal microscopy images of H22 cells after incubation with coumarin-6-loaded Rhodamine-B labeled PEG-PCL and Rhodamine-B labeled PEG-Pep-PCL nanoparticles. **(B)** The uptake efficiencies of coumarin-6-loaded PEG-PCL and PEG-Pep-PCL nanoparticles at different time points.

Notes: ** $P < 0.01$; *** $P < 0.0001$.

Abbreviations: PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.

ticles, the cellular uptake of PEG-Pep-PCL (0.5 hours, $P < 0.01$; 2 hours, $P < 0.0001$; 4 hours, $P < 0.01$) clearly showed this trend (Figure 3B). Especially at 2 hours where the cellular uptake of PEG-Pep-PCL was 159.55% higher than that of PEG-PCL.

The real-time biodistribution in tumor bearing mice and in vivo antitumor effect of nanoparticles

The real-time biodistribution of two nanoparticles in H22 tumor bearing mice was measured by a non-invasive near-infrared fluorescence imaging owing to dye-labeled PCL chain ends. Figure 4 depicts the NIRF dye NIR-797 labeled DOC-TNPs and DOC-NPs in vivo distribution during 72 hours. One hour after IV injection, the fluorescence signals of DOC-TNPs were found in the tumor regions, however, the same signals were mostly observed on the abdomen, indicating a fast hepatobiliary excretion tract. As time went on, the abdomen NIR fluorescence signals decreased, while the tumor signals became higher. Interestingly, the increasing NIR fluorescence densities of tumor zones were not observed in the DOC-NPs treated mice. Furthermore, at 48 hours post-injection, few fluorescence signals from PEG-PCL could be observed, suggesting a large amount of PEG-PCL nanoparticles were eliminated from the body. The fluorescence signals of PEG-Pep-PCL group in the tumor regions of DOC-TNPs were always stronger than the signals of the DOC-NPs group during the whole 72 hours, suggesting that DOC-TNPs preferred to concentrate and retain in the tumor regions. NIR fluorescence signals were clearly observed for NIR-797 labeled PEG-PCL nanoparticles, which were likely mediated by the enhanced permeability and retention (EPR) effect and the stealth effect afforded by PEGylation.




Figure 4 In vivo NIRF images of H22 tumor bearing mice following intravenous administration of NIR-797 labeled DOC-NPs and DOC-TNPs during 72 hours. The tumors were marked by arrows.

Abbreviations: DOC-NP, docetaxel-loaded nanoparticle; DOC-TNP, tumor-targeted docetaxel-loaded nanoparticle; NIR, near-infrared; NIRF, near-infrared fluorescent.

The in vivo antitumor studies of DOC-TNPs were performed on H22 tumor bearing mice, which highly expressed gelatinases. DOC-TNPs were given by intravenous administration every sixth day for 21 days. Saline, empty PEG-PCL nanoparticles, empty PEG-Pep-PCL nanoparticles, Taxotere®, and DOC-NPs were also given as controls for comprehensive comparison. On day 21 after the first treatment, the tumor inhibition rates in DOC-NPs and DOC-TNPs treated groups were 39.52% and 55.14%, respectively (Figure 5A). The DOC-TNPs treated group showed the highest antitumor efficiency and the smallest tumor volumes ($P < 0.01$ of 10 mg/kg Taxotere® equal; $P < 0.01$ of 10 mg/kg DOC-NPs equal).

The pathology examination clearly demonstrated the significant therapeutic efficacy of DOC-TNPs. The tumors in each experimental group were obtained 21 days after treatment and the paraffin tumor slices stained by H&E were used to evaluate the necrosis levels of tumors. Small necrotic regions were observed in the saline, empty PEG-PCL and empty PEG-Pep-PCL treated groups (Figure 5B). The Taxotere® treated group displayed a larger necrotic region surrounded with numerous active cancer cells. A much larger necrotic level could be observed in the nanotherapeutic groups, especially in the DOC-TNPs treated group.

The real time therapeutic effects of DOC-TNPs, DOC-NPs and Taxotere® on tumor activity were compared using positron emission tomography/computer tomography of deoxy-2-[^{18}F]Fluoro-D-glucose (^{18}F FDG-PET/CT). The advantages of this technique include the visualization and quantification of disseminated tumors' metabolism of tumor cells without the need of animal sacrifice for analysis. PET scanning images clearly revealed invisible metabolic activity within the transplanted tumors of the DOC-TNPs treated mice, and CT results confirmed the slowest tumor growth in this group. As displayed by Figure 6, the mice treated with Taxotere® demonstrated the highest signal intensity, mice treated with DOC-NPs and DOC-TNPs presented gradually decreased signals. The mean SUVs of tumors in the mice that received Taxotere®, DOC-NPs and DOC-TNPs were 0.83 ± 0.07 , 0.47 ± 0.06 , 0.20 ± 0.01 , respectively. As the CT imaging described, the tumor volume of Taxotere® treated mice was about 1000 mm³, while the tumors of DOC-NPs and DOC-TNPs treated groups were smaller, about 500 and 300 mm³, respectively.

Discussion

PEG-Pep-PCL nanoparticles, which contained the active peptide substrates of gelatinases, were prepared to improve




Figure 5 In vivo antitumor effects of different groups. **(A)** The tumor growth curves of H22 tumor-bearing mice that received different treatments. The same DOC dose (10 mg/kg) was given by intravenous injection on days 1, 7 and 13 (marked by arrows). For Taxotere®, DOC-NPs and DOC-TNPs. $**P < 0.01$ versus Taxotere® treated group or DOC-NPs group. **(B)** H&E stained slices of tumors from mice on the day 21 at the end of treatment with saline (a), empty PEG-PCL nanoparticles (b), empty PEG-Pep-PCL nanoparticles (c), Taxotere® (d) (10 mg/kg), DOC-NPs (e) (10 mg/kg DOC equal), DOC-TNPs (f) (10 mg/kg DOC equal) ($\times 40$).

Abbreviations: DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; H&E, hematoxylin and eosin; PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.

delivery of chemotherapeutic agents to tumor tissues and cells. We confirmed the gelatinase-responsive PEG-Pep-PCL nanoparticles were not only effectively targeted to the tumor tissues but also were taken up into tumor cells, and exhibited distinguished antitumor potency when they were used to load

chemotherapeutic agent DOC. To emphasize the superiority of this nanoparticle, the PEG-PCL nanoparticles without targeting peptide were compared as the control. The PEG-Pep-PCL nanoparticles not only kept the passively targeted advantages of common nanocarriers, but also overcame some




Figure 6 PET/CT images of mice administered 100 μ Ci of 18F-FDG and scanned 30 minutes post injection. From up to down, CT, PET and fusion views. **(A)** Taxotere® (10 mg/kg DOC equal). **(B)** DOC-NPs (10 mg/kg DOC equal). **(C)** DOC-TNPs (10 mg/kg DOC equal).

Abbreviations: CT, computed tomography; DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide; PET, positron emission tomography.

shortcomings of PEGylation. That is why PEG-TNPs showed high tumor growth suppression.

MMPs have received great attention in cancer research due to their important role in cancer progression. A variety of small-molecular MMPs inhibitors are under clinical trials or have been developed. However, few MMP inhibitors (MMPIs) are used clinically.^{26,27} The anticancer effects of MMPIs are mainly based on blocking either MMPs activity or secretion but the functions of MMPs are complex and variable. Some MMPs can accelerate tumor progression while others are protective. Specific MMPs even exhibit both positive and negative functions at different stages of the same disease. That's why the use of MMPIs in multiple clinical trials has often been aborted due to severe side-effects. We need to rethink how to better use MMPs in cancer therapeutics. As drug-activators for tumor therapeutic strategies, gelatinases have their own advantages. Firstly, instead of MMPs inhibitors disturbing the proteases synthesis, activity and function, the enzyme-responsive strategy just takes advantage of the hydrolytic functions of MMPs. The gelatinase-stimuli strategy can avoid the bottleneck in the development of MMPs inhibitors. Secondly, among various MMPs, gelatinases are significantly up-regulated in various malignant tumors, while almost undetectable in non-pathological environments. MMPs-stimuli strategy will exhibit superior antitumor effects with limited side effects on a number of cancers. Thirdly, gelatinases are widely known as tumor associated malignant enzymes and they are susceptible to recognize and hydrolyze IV collagen, a major component of the extracellular matrix (ECM). It is known that the ECM is the first barrier for invasive and metastasis tumor cells to overcome. Therefore, the gelatinase-stimuli strategy may present its advantages on primary tumors as well as micrometastatic or disseminated tumors.

During the past couple of years, PEGylation has been widely used in the development of intravenously injected drug delivery system.²⁸ PEGylation prolongs blood circulation, increases tumor accumulation, reduces serum protein adherence and creates a stealth surface to avoid the uptake by the reticuloendothelial systems (RES). PEGylated nanoparticles are also preferable with good biocompatibility, biodegradability, low antigenicity, and immunogenicity. However, recent work reported that the introduction of PEG chains on the surface of copolymers decreased endocytosis and hindered incorporation of into cells.^{23,29,30} In our cellular uptake studies, the gelatinase-stimuli strategy improved the low uptake of PEGylated nanoparticles in both attached and suspended cancer

cells, and the added value depended on the gelatinases' expression. This phenomenon may be ascribed to the dePEGylation caused by gelatinases. The gelatinases degraded the specific substrates, the linkers of hydrophilic PEG, and hydrophobic PCL blocks. The PEG conjugates were cleaved and the remaining PCL blocks gathered together for high hydrophobicity. The resulting PEG-uncoated nanoparticles had a higher affinity for cells than PEGylated nanoparticles, inducing more nanoparticles to enter tumor cells. Walker et al and Lee et al found such a trend in case of pH-triggering PEGylated-liposome and quantum dots (QD) with MMP-2 cleavage PEG conjugates.^{31,32} The enhanced cellular uptake of PEG-Pep-PCL nanoparticles is important for ideal therapeutic efficiency.

The gelatinases-stimuli DOC-TNPs, which could be transformed by both MMP-2 and MMP-9, showed distinguished tumor distribution dominance and antitumor efficiency over non-targeting DOC-NPs. Considering the synthesis feasibility and targeting specificity, we chose PVGLIG, a sequence with gelatinase selectivity, which has never been reported by other drug delivery studies,³³ as the bridge substrate of PEG and PCL blocks. Although, previous studies confirmed that MMP-2 cleavable liposomes could improve gene silencing effect.^{34,35} There remain many challenges in the protease-activatable area, including limited systemic evaluation and successful in vivo reports. The in vivo NIRF imaging clearly signified the gelatinases-stimuli profile altered the distribution of nanoparticles. The PEG-Pep-PCL nanoparticles can target and deliver to tumor tissues through EPR effect and PEGylation. Once arriving at the tumor tissues, the PEG conjugates were cleaved by tumor gelatinases and the PEG-uncoated particles aggregated. The gaps of tumor blood vessels are about 10–1000 nm,^{36,37} and larger particles are not easily extracted from tumor tissues. The penetration of nanoparticles is seriously impaired by some physiological barriers,^{38,39} especially the high interstitial fluid pressure. Small molecule drugs, such as DOC, diffused more easily in tumor tissues than nanoparticles. In vitro drug release studies showed gelatinase-stimuli profile induced DOC release quickly from PEG-Pep-PCL nanoparticles. This means dePEGylated nanoparticles not only induced drug accumulation in the tumors, but also delivered more drugs to tumor parenchyma and enhanced their efficacy. DOC-TNPs would enhance the distribution of the delivered drugs in the tumors and eradicate the tumors more completely. In the meantime, the nanoparticles that are accumulated in the liver and other tissues are able to clear, implying minimal side effects from these drugs.

Recent studies also found repeated injections of the conventional and noncleavable PEGylated nanoparticles could result in the “accelerated blood clearance (ABC)” phenomenon, which decreases antitumor effects and increase side effects.^{40,41} During the antitumor study, different DOC formations were given three times. As time went on, the difference of antitumor efficacy between DOC-TNPs and DOC-NPs became more obvious. Body weight variations, blood chemistry test and H&E-stained sections of main organs were also done to evaluate the adverse effects of different docetaxel formations (Figure S6 in the “Supplemental data”). The body weights in the group receiving DOC-NPs showed a remarkable loss compared with DOC-TNPs, especially on the last few days of the experiment. More recently, PEG-cleavage work^{42,43} showed that cleavable PEG derivatives on nanocarriers surface can weaken or eliminate the ABC phenomenon by reducing accumulation in liver and spleen. It is a clue for our design of the PEG-Pep-PCL nanoparticles, which should show similar effect on the ABC phenomenon. In fact, the data of the in vivo biodistribution of fluorescent nanoparticles show that the PEG-cleaved DOC-TNPs had less accumulation both in liver and spleen compared with DOC-NPs, indicating the gelatinases-specific strategy can improve pharmacokinetic and pharmacodynamic profiles. Thus, the gelatinase-cleavage of PEG could minimize or eliminate the shortages caused by ABC phenomenon.

This article is focused on the advantages of PEG-Pep-PCL nanoparticles in the tumor targeting and cellular uptake. Therefore, we concentrated on the gelatinase-stimuli property and the biodistribution of nanoparticles. As the current platform can be universally applied to almost any malignant tumors, and is adaptable to load a wide range of anticancer drugs, work on choosing the most suitable chemotherapy agents and animal models is currently underway and will likely demonstrate the techniques thoroughly. Consequently, the antitumor superiority of DOC-TNPs is associated with the following factors: (1) superior intracellular drug delivery; (2) maximal accumulation, delay and release in tumors; (3) reduced toxicity to other organs and tissues; (4) maintenance of the “passive targeting” advantages of nanoparticles.

Conclusion

In this paper, the gelatinase-stimuli PEG-Pep-PCL nanoparticles were prepared through inserting the enzyme-specific substrate between PEG and PCL blocks. Compared with PEG-PCL nanoparticles, the gelatinases strategy overcame some shortcomings of PEGylation, mediated specific,

and sufficient interactions with cancer cells and maximum nanoparticles distribution. In tumors, the convertible PEG-Pep-PCL nanoparticles entered tumor cells more easily than PEG-PCL nanoparticles by the dePEGylation of gelatinases. In vivo NIRF imaging revealed that DOC-TNPs have prominent tumor targeting ability. The PEG-Pep-PCL nanoparticles kept high tumor concentration at 72 h pi, while PEG-PCL nanoparticles were almost completely excreted from the mice. More importantly, the DOC-TNPs showed higher antitumor efficacy and lower toxicity than Taxotere®, DOC-NPs by the tumor volumes observation, histological staining as well as PET/CT imaging. These results imply that the PEG-Pep-PCL drug delivery system will provide a promising strategy to improve clinical cancer therapy while minimizing side effects.

Acknowledgments

This work has been supported by the National Natural Science Foundation of China (Nos 30872471, 81071815, 81001408) and international cooperation plan of Nanjing Science and Technology Bureau (No 201001137). We also thank Mr Tom Morse for his helpful advice in editing the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Farokhzad OC, Cheng J, Teplý BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. *Proc Natl Acad Sci U S A*. 2006;103(16):6315–6320.
2. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. *Nat Nanotechnol*. 2007;2(1):47–52.
3. Li LY, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. *Int J Radiat Oncol*. 2004;58(4):1215–1227.
4. Werner ME, Karve S, Sukumar R, et al. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. *Biomaterials*. 2011;32(33):8548–8554.
5. Tai WY, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. *J Control Release*. 2010;146(3):264–275.
6. Dai S, Ravi P, Tam KC. Thermo- and photo-responsive polymeric systems. *Soft Matter*. 2009;5(13):2513–2533.
7. Chen B, Cheng J, Wu Y, et al. Reversal of multidrug resistance by magnetic Fe₃O₄ nanoparticle copolymerizing daunorubicin and 5-bromotetrandrine in xenograft nude-mice. *Int J Nanomedicine*. 2009;4:73–78.
8. Konno T, Hasuda H, Ishihara K, Ito Y. Photo-immobilization of a phospholipid polymer for surface modification. *Biomaterials*. 2005;26(12):1381–1388.
9. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *J Control Release*. 2010;148(2):135–146.
10. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. *Nature Clinical Practice Oncology*. 2008;5(4):206–219.

11. Law B, Tung CH. Proteolysis: A biological process adapted in drug delivery, therapy, and imaging. *Bioconjugate Chem.* 2009;20(9):1683–1695.
12. Zhu L, Xie J, Swierczewska M, et al. Real-time video imaging of protease expression in vivo. *Theranostics.* 2011;1:18–27.
13. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jorgensen K. Drug delivery by phospholipase A(2) degradable liposomes. *Int J Pharm.* 2001;214(1–2):67–69.
14. Aimetti AA, Tibbitt MW, Anseth KS. Human neutrophil elastase responsive delivery from poly(ethylene glycol) hydrogels. *Biomacromolecules.* 2009;10(6):1484–1489.
15. Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. *Cell.* 2010;141(1):52–67.
16. Lopez-Otin C, Matrisian LM. Tumour micro environment-opinion-emerging roles of proteases in tumour suppression. *Nat Rev Cancer.* 2007;7(10):800–808.
17. Gupta GP, Massague J. Cancer metastasis: building a framework. *Cell.* 2006;127(4):679–695.
18. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. *J Clin Oncol.* 2009;27(31):5287–5297.
19. Albright CF, Graciani N, Han W, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. *Mol Cancer Ther.* 2005;4(5):751–760.
20. Terada T, Iwai M, Kawakami S, et al. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. *J Control Release.* 2006;111(3):333–342.
21. Elegbede AI, Banerjee J, Hanson AJ, et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. *J Am Chem Soc.* 2008;130(32):10633–10642.
22. Li RT, Li XL, Xie L, et al. Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. *Int J Pharm.* 2009;379(1):158–166.
23. Zhu ZS, Li Y, Li XL, et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. *J Control Release.* 2010;142(3):438–446.
24. Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. *J Control Release.* 2004;97(2):249–257.
25. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. *J Control Release.* 2007;118(1):7–17.
26. Fingleton B. MMPs as therapeutic targets - Still a viable option? *Semin Cell Dev Biol.* 2008;19(1):61–68.
27. Overall CM, Kleinfeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. *Brit J Cancer.* 2006;94(7):941–946.
28. Joralemon MJ, Mcrae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. *Chem Commun.* 2010;46(9):1377–1393.
29. Wu W, Li RT, Bian XC, et al. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. *Acs Nano.* 2009;3(9):2740–2750.
30. Karakoti AS, Das S, Thevuthasan S, Seal S. PEGylated inorganic nanoparticles. *Angew Chem Int Edit.* 2011;50(9):1980–1994.
31. Walker GF, Fella C, Pelisek J, et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. *Mol Ther.* 2005;11(3):418–425.
32. Lee S, Ryu JH, Park K, et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. *Nano Lett.* 2009;9(12):4412–4416.
33. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. *Nat Biotechnol.* 2001;19(7):661–667.
34. Hatakeyama H, Ito E, Akita H, et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. *J Control Release.* 2009;139(2):127–132.
35. Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. *Gene Ther.* 2007;14(1):68–77.
36. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. *Nat Rev Drug Discov.* 2010;9(8):615–627.
37. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. *J Cell Biol.* 2010;188(6):759–768.
38. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. *Cancer Res.* 2008;68(10):3795–3802.
39. Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. *Int J Nanomedicine.* 2007;2(2):265–274.
40. Mizushima T, Ishihara T, Takeda M, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. *Pharmaceut Res.* 2009;26(10):2270–2279.
41. Park K. To PEGylate or not to PEGylate, that is not the question. *J Control Release.* 2010;142(2):147–148.
42. Chen D, Liu W, Shen Y, Mu H, Zhang Y, Liang R, et al. Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. *Int J Nanomedicine.* 2011;6:2053–2061.
43. Xu H, Wang KQ, Chen DW, Deng YH. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. *Biomaterials.* 2010;31(17):4757–4763.

Electronic supplementary data

Materials and methods

Docetaxel and Taxotere® were kindly provided by Jiangsu Hengrui Medicine Company (Jiangsu, China). RPMI 1640 and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were purchased from Sigma Chemical Company (St Louis, MO). Murine hepatic carcinoma cell line H22 and human colon carcinoma cell line LOVO were purchased from Shanghai Institute of Cell Biology (Shanghai, China).

Particle size and morphology characterization

¹H-NMR spectra were recorded on an AVANCE 300 MHz spectrometer (Bruker, Germany) using chloroform-d₁ as solvent separately in 5 mm NMR tubes. In all the spectra tetramethylsilane (TMS) was used as the internal reference.

The nanoparticles were suspended in distilled water to achieve an appropriate level of scattering. Particle size and polydispersity of PEG-Pep-PCL and PEG-PCL were measured by dynamic light scattering (DLS) using a Brookhaven BI-9000 AT system (Brookhaven Instruments Corporation, Long Island, NY). Each sample was diluted to filtered water and measured for three times.

Drug loading content and encapsulation efficiency

The lyophilized Doc-loaded nanoparticles were dissolved in methanol (HPLC grade, Merck Sharp and Dohme, Whitehouse Station, NJ) and sonicated for 15 minutes, centrifuged at 1200 g for 5 minutes. The supernatant fractions were prepared for HPLC analysis.

Chromatographic separation was achieved using a HC-C18 column (250 × 4.6 mm, 5 μm), (Agilent Technologies, Palo Alto, CA) at 35°C. The mobile phase consisted of 50/50 double-distilled water (Millipore, Milford, MA)/acetonitrile (HPLC grade, Merck Sharp and Dohme). The flow rate was set to 1.0 mL/minute, UV detection wavelength was 230 nm. The retention time of DOC was about 3.4 minutes. The drug loading content and encapsulation efficiency were calculated by equations (1) and (2), respectively.

$$\text{Drug loading content \%} = \frac{\text{Weight of the drug in nanoparticles}}{\text{Weight of the nanoparticles}} \times 100\% \quad (1)$$

$$\text{Encapsulation efficiency \%} = \frac{\text{Weight of the drug in nanoparticles}}{\text{Weight of the feeding drug}} \times 100\% \quad (2)$$

Gelatin zymography

Gelatin zymography was used to quantify the active MMP-2 and MMP-9 extracellular levels. Briefly, 100 μL culture medium was subjected to SDS-PAGE in a gel containing 10 mg/mL of gelatin. The gels were then incubated in 2.5% Triton X-100 for 2 hours and rinsed in nanopure distilled H₂O. Gels were further incubated at 37°C for 24 hours in 200 mM NaCl, 5 mM CaCl₂, 0.02% Brij-35, 50 mM Tris-HCl buffer (pH 8.8), 1 μM ZnCl₂, then stained with 0.2% Coomassie brilliant blue R-250, and destained in 10% acetic acid and 30% methanol in H₂O. Gelatinolytic activity was detected as unstained bands on a blue background. Three independent experiments were performed.

Immunohistochemistry

Tumor samples fixed in 10% neutral buffered formalin were embedded in paraffin using automatic embedding equipment, after which 5-μm sections were prepared. Immunohistochemical analysis for MMP-9 and MMP-2 was done on paraffin-embedded H22 tumor sections of mice.

Side effects study

On Day 21 after treatment, the tissues including tumor, liver, spleen, lung, kidney and heart from the tested groups treated were dissected and fixed in 10% neutral buffered formalin. The tissues were processed routinely into paraffin, sectioned at a thickness of 5 μm, stained with H&E, and examined by optical microscope. The blood biochemistry and weights of all tested mice were also scrutinized.

Results




Figure S1 Synthesis scheme of PEG-Pep-PCL copolymers.

Abbreviations: PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.




Figure S2 ¹H nuclear magnetic resonance spectra (300 MHz, 25°C) of polymers in CDCl₃: (A) PEG-Pep-PCL copolymers; (B) PEG-PCL copolymers.

Note: The insert in (A) shows the proton signal from methyl groups in peptide (0.816–1.032 ppm), thus indicating portions of peptide were successfully conjugated into the copolymers.

Abbreviations: PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.

Table S1 Characterization of the DOC-TNPs and DOC-NPs

Nanoparticles	Diameter (nm)	Polydispersity index	Drug loading content (%)	Drug encapsulation efficiency (%)
DOC-TNP	85.7	0.131	20.3	80.7
DOC-NP	89.9	0.140	19.0	75.7

Abbreviations: DOC-NP, docetaxel-loaded nanoparticle; DOC-TNP, tumor-targeted docetaxel-loaded nanoparticle.




Figure S3 In vitro DOC release of DOC-TNPs and DOC-NPs in phosphate buffered saline.

Abbreviations: DOC, docetaxel; DOC-NPs, docetaxel-loaded nanoparticles; DOC-TNPs, tumor-targeted docetaxel-loaded nanoparticles; PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.




Figure S4 Detection of gelatinases by gelatin zymography, which can quantitatively measure the activity of gelatinases (MMP2/9). Following the Coomassie blue staining, gelatinases activity is detected as a white zone on black background and quantified by densitometry. (A) Scanning images of the gelatin zymography for LLC and LOVO cancer cells. (B) The expressions of LLC and LOVO cells for MMP-2 and MMP-9 by a semi-quantitative technique.

Abbreviations: LLC, Lewis lung carcinoma; MMP, matrix metalloproteases.




Figure S5 (A) Gelatin zymography of the gelatinases (MMP2/9) expression by in H22 cells. (B) Immunohistochemical analysis of the gelatinases (MMP2/9) expression in H22 tumours ($\times 100$).

Abbreviation: MMP, matrix metalloproteases.




Figure S6 (A) Body weight curves of each group during the whole experiment. (B) Blood chemistry ALT and AST test was performed on Day 21 after initiation of the treatment. (C) Blood chemistry BUN and Cr test was performed on Day 21 after initiation of the treatment. (D) Abnormal damage was not observed in the H&E stained sections of main organs ($\times 40$). The result was consistent with the normal hepatic enzyme levels measured in the blood test (a) saline; (b) empty PEG-PCL nanoparticles; (c) empty PEG-Pep-PCL nanoparticles; (d) Taxotere®; (e) DOC-NPs; (f) Doc-TNPs.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; DOC-NP, docetaxel-loaded nanoparticle; DOC-TNP, tumor-targeted docetaxel-loaded nanoparticle; H&E, hematoxylin and eosin; PCL, poly(ϵ -caprolactone); PEG, poly(ethylene glycol); Pep, peptide.